H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
16 th Congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n<br />
with acute mye<strong>lo</strong>id leukaemia: a web-based applicat<strong>io</strong>n for<br />
predict<strong>io</strong>n of outcomes. Lancet. 2010;376:2000-8.<br />
21. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L,<br />
Stockelberg D, et al. Age and acute mye<strong>lo</strong>id leukemia: real<br />
world data on decis<strong>io</strong>n to treat and outcomes from the<br />
Swedish Acute Leukemia Registry. B<strong>lo</strong>od. 2009;113:4179-87.<br />
22. Juliusson G, Karlsson K, Hallbook H. Populat<strong>io</strong>n-based analyses<br />
in adult acute lymphoblastic leukemia. B<strong>lo</strong>od. 2010;116:<br />
1011; author reply 2.<br />
23. Ferrari A, Annino L, Crescenzi S, Romani C, Mandelli F. Acute<br />
lymphoblastic leukemia in the elderly: results of two different<br />
treatment approaches in 49 patients during a 25-year per<strong>io</strong>d.<br />
Leukemia. 1995;9:1643-7.<br />
24. Tay<strong>lo</strong>r PR, Reid MM, Proctor SJ. Acute lymphoblastic<br />
leukaemia in the elderly. Leuk Lymphoma. 1994;13:373-80.<br />
25. Delannoy A, Ferrant A, Bosly A, Chatelain C, Doyen C,<br />
Martiat P, et al. Acute lymphoblastic leukemia in the elderly.<br />
Eur J Haematol. 1990;45:90.<br />
26. Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao<br />
H, et al. [Analysis of elderly patients, aged 60 years old or over,<br />
with acute lymphoblastic leukemia]. Nippon Ronen Igakkai<br />
Zasshi. 1999;36:52-8.<br />
27. Onciu M, Lai R, Kantarjian H, Ball G, Smith T, Buesco-Ramos<br />
C. Acute lymphoblastic leukemia (ALL) in the elderly - the significance<br />
of the philadelphia chromosome. B<strong>lo</strong>od. 2000;96:<br />
4558.<br />
28. Kantarjian HM, O’Brien S, Smith T, Estey EH, Beran M, Preti A,<br />
et al. Acute lymphocytic leukaemia in the elderly: characteristics<br />
and outcome with the vincristine-adriamycindexamethasone<br />
(VAD) regimen. Br J Haematol. 1994;88:94-100.<br />
29. Mandelli F, Annino L, Ferrari A, for the GG. ALL in elderly:<br />
The GIMEMA trials. Ann Hematol. 1995;70:41a.<br />
30. Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran<br />
M, et al. Results of treatment with hyper-CVAD, a dose-intensive<br />
regimen, in adult acute lymphocytic leukemia. J Clin<br />
Oncol. 2000;18:547-61.<br />
31. Todeschini G, Tecch<strong>io</strong> C, Meneghini V, Pizzola G, Krampera<br />
M, Ambrosetti A, et al. Acute lymphoblastic leukemia (ALL)<br />
in elderly patients receiving intensive treatment. Experience in<br />
26 consecutive patients. B<strong>lo</strong>od. 1996;88 (Suppl 1):170b.<br />
32. Bassan R, Di BE, Lerede T, Pogliani E, Rossi G, D’Emil<strong>io</strong> A, et<br />
al. Age-adapted moderate-dose induct<strong>io</strong>n and flexible outpatient<br />
postremiss<strong>io</strong>n therapy for elderly patients with acute<br />
lymphoblastic leukemia. Leuk Lymphoma. 1996;22:295-301.<br />
33. Delannoy A, Sebban C, Cony-Makhoul P, Cazin B,<br />
Cordonnier C, Bouabdallah R. et al. Age-adapted induct<strong>io</strong>n<br />
treatment of acute lymphoblastic leukemia in the elderly and<br />
assessment of maintenance with interferon combined with<br />
chemotherapy. A multicentric prospective study in forty<br />
patients. Leukemia. 1997;11:1429-34.<br />
34. Sancho JM, Ribera JM, Xicoy B, Minden, Schuh A, Schimmer<br />
A, et al. Results of the PETHEMA ALL-96 trial in elderly<br />
patients with Philadelphia chromosome-negative acute lymphoblastic<br />
leukemia. Eur J Haematol 2007;78:102-10.<br />
35. Kao S, Xu W, Gupta V, et al. Outcome of patients aged 60 and<br />
over with acute lymphoblastic leukemia (ALL) treated with a<br />
modified pediatric protocol. B<strong>lo</strong>od. 2008;112:3962a.<br />
36. Gökbuget N, Leguay T, Hunault M, Minden, Schuh A,<br />
Schimmer A, et al. First <strong>European</strong> Chemotherapy Schedule for<br />
Elderly Patients with Acute Lymphoblastic Leukemia:<br />
Promising Remiss<strong>io</strong>n Rate and Feasible Moderate Dose<br />
Intensity Consolidat<strong>io</strong>n. B<strong>lo</strong>od. 2008;112:304a.<br />
37. Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet<br />
F, Bonmati C, et al. A randomised study of pegylated liposomal<br />
doxorubicine versus continuous infus<strong>io</strong>n doxorubicine in<br />
elderly patients with acute lymphoblastic leukemia: the<br />
GRAALL-SA1 Study. Haemato<strong>lo</strong>gica. 2010;October 22, Epub.<br />
38. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F,<br />
Ferrara F, et al. Imatinib plus steroids induces complete remiss<strong>io</strong>ns<br />
and pro<strong>lo</strong>nged survival in elderly Philadelphia chromosome-positive<br />
acute lymphoblastic leukemia patients without<br />
addit<strong>io</strong>nal chemotherapy: results of the GIMEMA LAL0201-B<br />
protocol. B<strong>lo</strong>od. 2007;109:3676-8.<br />
39. Delannoy A, Delabesse E, Lheritier V, Castaigne S, Rigal-Huguet<br />
F, Raffoux E, et al. Imatinib and methylpredniso<strong>lo</strong>ne alternated<br />
with chemotherapy improve the outcome of elderly<br />
patients with Philadelphia-positive acute lymphoblastic<br />
leukemia: results of the GRAALL AFR09 study. Leukemia.<br />
2006;20:1526-32.<br />
40. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes<br />
M, Duhrsen U, et al. Imatinib compared with chemotherapy<br />
as front-line treatment of elderly patients with Philadelphia<br />
chromosome-positive acute lymphoblastic leukemia (Ph+ALL).<br />
Cancer. 2007;109:2068-76.<br />
41. Rousse<strong>lo</strong>t P, Cayuela JM, Hayette S, Recher C, Leguay T,<br />
Salanoubat C, et al. Dasatinib (Sprycel(R)) and <strong>lo</strong>w intensity<br />
chemotherapy for first-line treatment in elderly pateints with<br />
de novo philadelphia positive ALL (EWALL-PH-01): Kinetic of<br />
response, resistance and prognostic significance. B<strong>lo</strong>od. 2010;<br />
116:172a.<br />
42. Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM,<br />
Huguet F, et al. Treatment of acute lymphoblastic leukemia in the<br />
elderly: an evaluat<strong>io</strong>n of interferon alpha given as a single agent<br />
after complete remiss<strong>io</strong>n. Leuk Lymphoma. 2002;43:75-81.<br />
43. Hoelzer D, Hiddemann W, Baumann A, Döhner H, Dührsen<br />
U, Fietkau R, et al. High Survival Rate in Adult Burkitts<br />
Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma<br />
with Mediastinal Involvement. B<strong>lo</strong>od. 2007;110:abstract #518.<br />
44. Thomas DA, Kantarjian H, Cortes J, Faderl S, Ravandi-Kashani<br />
F, Wierda W, et al. Long-Term Outcome after Hyper-CVAD<br />
and Rituximab Chemoimmunotherapy for Burkitt (BL) or<br />
Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell<br />
Acute Lymphocytic Leukmia (B-ALL). B<strong>lo</strong>od. 2007;110:2825a.<br />
45. Hoelzer D, Huettmann A, Kaul F, Irmer S, Jaekel N, Mohren<br />
M, et al. Immunochemotherapy with Rituximab Improves<br />
Molecular CR Rate and Outcome In CD20+ B-Lineage<br />
Standard and High Risk Patients; Results of 263 CD20+<br />
Patients Studied Prospectively In GMALL Study 07/2003.<br />
B<strong>lo</strong>od. 2010;116:170a.<br />
46. Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A,<br />
Wierda W, et al. Chemoimmunotherapy With a Modified Hyper-<br />
CVAD and Rituximab Regimen Improves Outcome in De Novo<br />
Philadelphia Chromosome-Negative Precursor B-Lineage Acute<br />
Lymphoblastic Leukemia. J Clin Oncol. 2010;28:3880-9.<br />
47. Gökbuget N, Hoelzer D. Novel antibody-based therapy for<br />
acute lymphoblastic leukaemia. Best Pract Res Clin Haematol.<br />
2006;19:701-13.<br />
48. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop<br />
S, et al. Tumor regress<strong>io</strong>n in cancer patients by very <strong>lo</strong>w doses<br />
of a T cell-engaging antibody. Science. 2008;321:974-7.<br />
49. Topp M, Zugmaier G, Gökbuget N, Neumann S, Horst H, Raff<br />
T, et al. CD19/CD3 Bispecific Antibody Blinatumomab (MT-<br />
103) Is Highly Effective In Treatment of Patients with Minimal<br />
Residual Disease From Chemotherapy-Resistant B-Precursor<br />
Acute Lymphoblastic Leukemia. B<strong>lo</strong>od. 2010;116:174a.<br />
50. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P,<br />
Fernandez-Aviles F, et al. Al<strong>lo</strong>geneic hematopoietic stem cell<br />
transplantat<strong>io</strong>n with reduced-intensity condit<strong>io</strong>ning in acute<br />
lymphoblastic leukemia: a feasibility study. Haemato<strong>lo</strong>gica.<br />
2003;88:555-60.<br />
51. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen<br />
DW, Fauser AA, et al. Nonmye<strong>lo</strong>ablative stem cell transplantat<strong>io</strong>n<br />
in adults with high-risk ALL may be effective in early<br />
but not in advanced disease. Leukemia. 2002;16:2423-8.<br />
52. Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y, et al.<br />
Reduced-intensity stem-cell transplantat<strong>io</strong>n for adult acute<br />
lymphoblastic leukemia: a retrospective study of 33 patients.<br />
Bone Marrow Transplant. 2005;35:549-56.<br />
53. Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J,<br />
et al. Reduced-intensity versus convent<strong>io</strong>nal mye<strong>lo</strong>ablative<br />
condit<strong>io</strong>ning al<strong>lo</strong>geneic stem cell transplantat<strong>io</strong>n for patients<br />
with acute lymphoblastic leukemia: a retrospective study from<br />
the <strong>European</strong> Group for B<strong>lo</strong>od and Marrow Transplantat<strong>io</strong>n.<br />
B<strong>lo</strong>od. 2010;116:4439-43.<br />
54. Pulte D, Gondos A, Brenner H. Improvement in survival in<br />
younger patients with acute lymphoblastic leukemia from the<br />
1980s to the early 21st century. B<strong>lo</strong>od. 2009;113:1408-11.<br />
| 26 | Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1)
Change language